share_log

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

心脏疗法宣布完成价值1350万美元的普通股公开发行
newsfile ·  10/10 21:09

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

安大略省奥克维尔-(Newsfile公司-2024年10月10日)-心诺治疗公司(纳斯达克: CRDL)(TSX: CRDL)("心诺"或"公司"),一家专注于心脏疾病治疗的抗炎和抗纤维化疗法的临床生命科学公司,今天确认其已成功完成先前宣布的公开发行("发行"),以$1.60美元的价格每股发行了公司的8,437,500股A类普通股("普通股"),募资净额为1350万美元,未计算承销折扣、佣金和与发行相关的预计费用。

As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

公司如前所述,打算将这次发行募集的资金净额用于支持CardiolRx的临床开发,用于治疗复发性心包炎以及一般和管理费用、营运资金和其他费用。

Canaccord Genuity acted as the sole bookrunner in connection with the Offering.

Canaccord Genuity担任本次发行的唯一主承销商。

The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the "SEC") on July 16, 2024 (the "Registration Statement"), and the Company's existing Canadian short form base shelf prospectus (the "Base Prospectus") dated July 12, 2024. A preliminary prospectus supplement relating to the Offering was filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to the Offering (the "Supplement") was filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

此次发行根据于2024年7月16日("注册声明生效日")由美国证券交易委员会("SEC")宣布生效的F-10表格的美国注册声明("注册声明")以及于2024年7月12日日期的公司现有加拿大短期基础展示文件("基础展示文件")进行。与发行相关的初步招股说明书补充已在除魁北克省外的加拿大所有省和地区的证券监管部门以及美国的SEC进行了申报,相关的最终招股说明书补充("补充")已在除魁北克省外的加拿大所有省和地区的证券监管部门以及美国的SEC进行了申报。补充和伴随的基础展示文件包含有关发行的重要详细信息。

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Canaccord Genuity LLC, 1 Post Office Square, Suite 3000, Boston, Massachusetts 02109, Attn: Syndicate Department, or by email at prospectus@cgf.com.

补充和伴随的基础展示文件可在SEDAR+ 和EDGAR网站的www.sec.gov上找到。补充和伴随的基础展示文件副本也可从Canaccord Genuity LLC, 1 Post Office Square, Suite 3000, Boston, Massachusetts 02109, 邮编:02109的Syndicate Department处获得,或通过prospectus@cgf.com发送电子邮件获取。

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

此新闻稿不构成出售或要约出售任何省、州或司法管辖区的证券,该等出售或要约出售在该等省、州或司法管辖区内是不合法的,并且在任何此类证券根据任何该省、州或司法管辖区的证券法律法规进行注册或合格之前,不得出售。

About Cardiol Therapeutics

关于Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.

Cardiol Therapeutics Inc.是一家临床阶段的生命科学公司,专注于研究和临床开发抗炎和抗纤维化疗法,用于治疗心脏疾病。

Cautionary statement regarding forward-looking information:

关于前瞻性信息的警示声明:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the anticipated use of proceeds from the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

本新闻发表包含"前瞻性信息",依适用证券法规定。除历史事实陈述外,所有涉及Cardiol公司认为、预期或预测将来可能会发生的活动、事件或发展的陈述均为"前瞻性信息"。此处的前瞻性信息可能包括但不限于关于配售所得款项预期使用的声明。此处的前瞻性信息反映了Cardiol公司基于当前已获其可用信息并基于某些假设的当前期望或信念,同时也受各种已知和未知风险、不确定因素和其他可能导致实际事件或结果与前瞻性信息所表达或暗示的任何未来结果、表现或成就存在重大差异的因素影响,不(且不应被视为)对未来表现的保证。这些风险、不确定因素和其他因素包括在公司于2024年4月1日向美国证券交易委员会和加拿大证券监管机构提交的年度报告Form 20-F中提及的风险和不确定因素,以及与产品商业化和临床研究相关的风险和不确定因素。这些假设、风险、不确定因素和其他因素应慎重考虑,投资者不应过分依赖前瞻性信息,该信息可能不适用于其他目的。任何前瞻性信息仅于本新闻发布日期作出表述,除适用证券法要求外,Cardiol公司不声明有意或有义务更新或修订此类前瞻性信息,无论是基于新信息、未来事件或结果或其他原因。投资者应谨慎不依赖这些前瞻性声明,并鼓励阅读补充、随附的基本招股说明书以及被引入其中的文件。

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

如需更多信息,请联系:
投资者关系 Trevor Burns +1-289-910-0855 trevor.burns@cardiolrx.com
投资者关系 Trevor Burns +1-289-910-0855 trevor.burns@cardiolrx.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发